US5183884A
(en)
|
1989-12-01 |
1993-02-02 |
United States Of America |
Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
|
US6639061B1
(en)
|
1999-07-07 |
2003-10-28 |
Isis Pharmaceuticals, Inc. |
C3′-methylene hydrogen phosphonate oligomers and related compounds
|
US5804396A
(en)
|
1994-10-12 |
1998-09-08 |
Sugen, Inc. |
Assay for agents active in proliferative disorders
|
WO1996014864A1
(en)
|
1994-11-09 |
1996-05-23 |
The Regents Of The University Of California |
Immunoliposomes that optimize internalization into target cells
|
DK0896586T4
(en)
|
1996-03-27 |
2015-08-24 |
Genentech Inc |
ErbB3 antibodies.
|
CA2589421C
(en)
|
1996-03-27 |
2012-12-18 |
Genentech, Inc. |
Erbb3 antibodies
|
US5968511A
(en)
|
1996-03-27 |
1999-10-19 |
Genentech, Inc. |
ErbB3 antibodies
|
US5922845A
(en)
|
1996-07-11 |
1999-07-13 |
Medarex, Inc. |
Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
|
DE69740038D1
(pt)
|
1996-07-12 |
2010-12-16 |
Genentech Inc |
|
US20020002276A1
(en)
|
1997-02-10 |
2002-01-03 |
Genentech, Inc. |
Chimeric heteromultimer adhesins
|
US6723694B1
(en)
|
1997-05-21 |
2004-04-20 |
The Children's Medical Center Corp. |
Short peptides which selectively modulate intracellular signalling
|
US6416168B1
(en)
|
1997-07-15 |
2002-07-09 |
Silverbrook Research Pty Ltd |
Pump action refill ink jet printing mechanism
|
ZA9811162B
(en)
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
AU2003203831B2
(en)
|
1998-02-04 |
2006-08-10 |
Genentech, Inc. |
Use of heregulin as an epithelial cell growth factor
|
US20010023241A1
(en)
|
1998-02-04 |
2001-09-20 |
Sliwkowski Mark X. |
Use of heregulin as a growth factor
|
AU2581599A
(en)
|
1998-02-04 |
1999-08-23 |
Genentech Inc. |
Use of heregulin as an epithelial cell growth factor
|
US6417168B1
(en)
|
1998-03-04 |
2002-07-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of treating tumors
|
DE69939374D1
(de)
|
1998-03-17 |
2008-10-02 |
Genentech Inc |
Zu vegf und bmp1 homologe polypeptide
|
WO1999054342A1
(en)
|
1998-04-20 |
1999-10-28 |
Pablo Umana |
Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
|
WO1999060023A1
(en)
|
1998-05-15 |
1999-11-25 |
Imclone Systems Incorporated |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
|
AU2004200705A1
(en)
|
1998-05-15 |
2004-03-18 |
Imclone Systems Incorporated |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
|
ZA200007412B
(en)
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
MXPA01004544A
(es)
|
1998-11-07 |
2002-07-30 |
Genentech Inc |
Metodo para mejorar la proliferacion de las celulas pilosas del oido interno utilizando ligandos para los receptores her2 y/o her3.
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
EP1169352A4
(en)
*
|
1999-04-14 |
2005-05-04 |
Smithkline Beecham Corp |
ANTIBODY AGAINST THE ERYTHROPOIETIN RECEPTOR
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
US6710186B2
(en)
|
1999-06-14 |
2004-03-23 |
Wisconsin Alumni Research Foundation |
Oligomers and polymers of di-substituted cyclic imino carboxylic acids
|
AUPQ105799A0
(en)
|
1999-06-18 |
1999-07-08 |
Victor Chang Cardiac Research Institute, The |
Cell growth inhibition
|
ES2329437T3
(es)
|
1999-06-25 |
2009-11-26 |
Genentech, Inc. |
Anticuerpos anti-erbb2 humanizados y tratamiento con anticuerpos anti-erbb2.
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
DK2803367T3
(en)
|
1999-06-25 |
2018-04-16 |
Immunogen Inc |
Methods of treatment using anti-ERBB antibody-maytansinoid conjugates
|
US6627196B1
(en)
|
1999-08-27 |
2003-09-30 |
Genentech, Inc. |
Dosages for treatment with anti-ErbB2 antibodies
|
US7390632B2
(en)
|
1999-09-30 |
2008-06-24 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 receptor isoforms
|
US7732157B1
(en)
|
1999-09-30 |
2010-06-08 |
Tumor Biology Investment Group |
Soluble epidermal growth factor receptor-like proteins and their uses in cancer detection methods
|
US7651703B2
(en)
|
1999-10-15 |
2010-01-26 |
Genentech, Inc. |
Injection vehicle for polymer-based formulations
|
EP1247098A1
(en)
|
2000-01-12 |
2002-10-09 |
Ventana Medical Systems, Inc. |
Method for quantitating a protein by image analysis
|
DE60028830T2
(de)
|
2000-02-16 |
2007-01-18 |
Genentech, Inc., South San Francisco |
Anti-april antikörper und hybridomazellen
|
US6632979B2
(en)
|
2000-03-16 |
2003-10-14 |
Genentech, Inc. |
Rodent HER2 tumor model
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
AU2007216733A1
(en)
|
2000-04-11 |
2007-09-27 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
CN101289511A
(zh)
|
2000-04-11 |
2008-10-22 |
杰南技术公司 |
多价抗体及其应用
|
FR2807767B1
(fr)
|
2000-04-12 |
2005-01-14 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-d
|
AUPQ903400A0
(en)
|
2000-07-27 |
2000-08-17 |
Oh, Young June |
Navigable search engine
|
US6277640B1
(en)
|
2000-07-31 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of Her-3 expression
|
ATE356575T1
(de)
|
2000-11-24 |
2007-04-15 |
Freudenberg Carl Kg |
Bodenwischer
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
AU2008200400B2
(en)
|
2001-01-17 |
2012-06-07 |
Aptevo Research And Development Llc |
Binding domain-immunoglobulin fusion proteins
|
EP1228766A1
(en)
|
2001-01-31 |
2002-08-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
PYK2 phosphorylation by HER3 induces tumor invasion
|
CA2437814C
(en)
|
2001-02-12 |
2008-05-13 |
Medarex, Inc. |
Human monoclonal antibodies to fc alpha receptor (cd89)
|
WO2002081649A2
(en)
|
2001-04-06 |
2002-10-17 |
The Trustees Of The University Of Pennsylvania |
ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
|
WO2002087618A1
(fr)
|
2001-04-27 |
2002-11-07 |
Takeda Chemical Industries, Ltd. |
Methode de prevention et de traitement du cancer
|
CZ20033143A3
(en)
|
2001-05-21 |
2004-04-14 |
Aclara Biosciences, Inc. |
Methods and compositions for analyzing proteins
|
US7744882B2
(en)
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 methods of detection and antibodies
|
US7745398B2
(en)
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 and treatment of cancer
|
AU2002314495A1
(en)
|
2001-06-20 |
2003-01-02 |
Prochon Biotech Ltd. |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
US7276658B2
(en)
|
2001-06-21 |
2007-10-02 |
Akzo Nobel N.V. |
Manufacturing a solar cell foil connected in series via a temporary substrate
|
US7125680B2
(en)
|
2001-07-27 |
2006-10-24 |
The Regents Of The University Of California |
Methods and materials for characterizing and modulating interaction between heregulin and HER3
|
DE10137374A1
(de)
|
2001-07-31 |
2003-02-27 |
Ipk Inst Fuer Pflanzengenetik |
Verfahren zur Herstellung von Arachidonsäure in transgenen Organismen
|
US7662374B2
(en)
|
2001-08-03 |
2010-02-16 |
The Trustees Of The University Of Pennsylvania |
Monoclonal antibodies to activated erbB family members and methods of use thereof
|
AU2008200654B2
(en)
|
2001-08-09 |
2010-04-29 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Inhibitors of HER3 activity
|
EP1283053A1
(en)
*
|
2001-08-09 |
2003-02-12 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Inhibitors of HER3 activity
|
US8877901B2
(en)
|
2002-12-13 |
2014-11-04 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
JP4132912B2
(ja)
|
2002-03-26 |
2008-08-13 |
日東電工株式会社 |
ゲル電解質とその製造方法とその利用
|
US7919098B2
(en)
|
2002-03-26 |
2011-04-05 |
Zensun ( Shanghai ) Sci & Tech Co., Ltd. |
ErbB-3 based methods and compositions for treating neoplasms
|
US7332580B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The University Of California |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
JP4319979B2
(ja)
|
2002-04-26 |
2009-08-26 |
ジェネンテック・インコーポレーテッド |
タンパク質の非アフィニティ精製
|
US20040229299A1
(en)
|
2002-05-21 |
2004-11-18 |
Badal M. Youssouf |
Intracellular complexes as biomarkers
|
US20040229294A1
(en)
|
2002-05-21 |
2004-11-18 |
Po-Ying Chan-Hui |
ErbB surface receptor complexes as biomarkers
|
US20040229380A1
(en)
|
2002-05-21 |
2004-11-18 |
Po-Ying Chan-Hui |
ErbB heterodimers as biomarkers
|
US20040229293A1
(en)
|
2002-05-21 |
2004-11-18 |
Po-Ying Chan-Hui |
Surface receptor complexes as biomarkers
|
US20040132097A1
(en)
|
2002-06-19 |
2004-07-08 |
Bacus Sarah S. |
Method for predicting response to epidermal growth factor receptor-directed therapy
|
PL214010B1
(pl)
|
2002-07-15 |
2013-06-28 |
Genentech Inc |
Rekombinowane humanizowane przeciwcialo 2C4 i zastosowanie tego przeciwciala
|
ATE442589T1
(de)
|
2002-07-25 |
2009-09-15 |
Aclara Biosciences Inc |
Nachweis der rezeptoroligomerisierung
|
GB0225282D0
(en)
|
2002-10-31 |
2002-12-11 |
Astrazeneca Ab |
assay
|
CA2513113A1
(en)
|
2003-01-23 |
2004-08-05 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
CN1798770B
(zh)
|
2003-04-04 |
2010-06-09 |
洛桑大学 |
用于治疗癌症的多聚肽体
|
US7189694B2
(en)
|
2003-04-18 |
2007-03-13 |
University Of Florida Research Foundation, Inc. |
Inhibitors of autophosphorylation protein kinases
|
EP2348110B1
(en)
|
2003-05-30 |
2013-03-27 |
OncoTherapy Science, Inc. |
Process for screening a drug response in cancer patients
|
PL1636593T3
(pl)
|
2003-06-06 |
2009-08-31 |
Genentech Inc |
Modulowanie oddziaływania pomiędzy łańcuchem beta HGF i c-met.
|
WO2005001048A2
(en)
|
2003-06-13 |
2005-01-06 |
Oncomax Acquisition Corp. |
Preparation and application of anti-tumor bifunctional fusion proteins
|
US20040254108A1
(en)
|
2003-06-13 |
2004-12-16 |
Jing Ma |
Preparation and application of anti-tumor bifunctional fusion proteins
|
US20050232931A1
(en)
|
2003-06-13 |
2005-10-20 |
Oncomax Acquisition Corp. |
Preparation and application of anti-tumor bifunctional fusion proteins
|
US6836094B1
(en)
|
2003-07-01 |
2004-12-28 |
International Truck Intellectual Property Company, Llc |
Motor vehicle battery disconnect switch circuits
|
US7531649B2
(en)
|
2003-07-18 |
2009-05-12 |
The Regents Of The University Of California |
Aptamers to human epidermal growth factor receptor-3
|
AU2004265253B2
(en)
|
2003-07-28 |
2011-09-01 |
Genentech, Inc. |
Reducing protein A leaching during protein A affinity chromatography
|
EP1651095A4
(en)
|
2003-08-05 |
2008-10-08 |
Euro Celtique Sa |
ErbB RECEPTOR PROCESS AND SETS FOR MONITORING CHEMOTHERAPY RESISTANCE
|
WO2005014618A2
(en)
|
2003-08-08 |
2005-02-17 |
Immunomedics, Inc. |
Bispecific antibodies for inducing apoptosis of tumor and diseased cells
|
BRPI0413471A
(pt)
|
2003-08-11 |
2006-10-17 |
Monogram Biosciences Inc |
métodos para detectar um ou mais complexos de proteìnas e para detectar um complexo em uma amostra biológica
|
US8399618B2
(en)
|
2004-10-21 |
2013-03-19 |
Xencor, Inc. |
Immunoglobulin insertions, deletions, and substitutions
|
US7402399B2
(en)
|
2003-10-14 |
2008-07-22 |
Monogram Biosciences, Inc. |
Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
|
EP1680666A4
(en)
|
2003-10-27 |
2008-03-26 |
Monogram Biosciences Inc |
ANTI-THERAPEUTIC HUMAN ANTIBODY DETECTION
|
MXPA06005024A
(es)
|
2003-11-06 |
2006-07-06 |
Pfizer Prod Inc |
Combinaciones de inhibidor de erbb2 selectivo/anticuerpos anti-erbb en el tratamiento del cancer.
|
US7754441B2
(en)
|
2003-11-17 |
2010-07-13 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
CA2551813C
(en)
|
2003-12-24 |
2014-08-12 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
US8323987B2
(en)
|
2004-02-17 |
2012-12-04 |
The University Of North Carolina At Chapel Hill |
Modulation of epidermal growth factor heterodimer activity
|
WO2005081898A2
(en)
|
2004-02-20 |
2005-09-09 |
The Trustees Of The University Of Pennsylvania |
Binding peptidomimetics and uses of the same
|
EP1796711A2
(en)
|
2004-04-22 |
2007-06-20 |
Oregon Health and Science University |
Herstatin or intron 8-encoded domain thereof for modulating signaling mediated by igf-1 receptor and erbb receptors
|
WO2005117973A2
(en)
|
2004-05-05 |
2005-12-15 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents for modulating biological activity
|
WO2005118642A2
(en)
|
2004-06-01 |
2005-12-15 |
Domantis Limited |
Bispecific fusion antibodies with enhanced serum half-life
|
BRPI0510883B8
(pt)
|
2004-06-01 |
2021-05-25 |
Genentech Inc |
composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
|
GT200500155A
(es)
|
2004-06-16 |
2006-05-15 |
|
Terapia del càncer resistente al platino
|
EP1781689A4
(en)
|
2004-06-24 |
2010-11-10 |
Inst Medical W & E Hall |
CONJUGATES AND THEIR THERAPEUTIC APPLICATIONS
|
KR20150140417A
(ko)
|
2004-07-22 |
2015-12-15 |
제넨테크, 인크. |
Her2 항체 조성물
|
KR101270829B1
(ko)
|
2004-09-23 |
2013-06-07 |
제넨테크, 인크. |
시스테인 유전자조작 항체 및 접합체
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
CA2583230A1
(en)
|
2004-10-05 |
2006-04-20 |
Oregon Health And Science University |
Compositions and methods for treating disease
|
CA2587617C
(en)
|
2004-11-12 |
2011-02-01 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
JP2008520745A
(ja)
|
2004-11-22 |
2008-06-19 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Rhoキナーゼの二環式阻害剤
|
US7947839B2
(en)
|
2004-12-01 |
2011-05-24 |
Genentech, Inc. |
Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
|
WO2006060419A2
(en)
*
|
2004-12-03 |
2006-06-08 |
Schering Corporation |
Biomarkers for pre-selection of patients for anti-igf1r therapy
|
ZA200704796B
(en)
|
2004-12-07 |
2008-11-26 |
Genentech Inc |
Selecting patients for therapy with a HER inhibitor
|
US7807789B2
(en)
|
2004-12-21 |
2010-10-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
|
EP1841882A1
(en)
|
2004-12-21 |
2007-10-10 |
Cell Signaling Technology, Inc. |
Protein phosphorylation in egfr-signaling pathways
|
PT2028193E
(pt)
|
2005-01-05 |
2012-06-15 |
Star Biotech Forschung Entw Gmbh |
Domínios de imunoglobulina sintéticos com propriedades de ligação modificadas em regiões da molécula diferentes das regiões de determinação de complementaridade
|
WO2006076041A2
(en)
|
2005-01-11 |
2006-07-20 |
Molecular Logix, Inc. |
Pan-her antagonists and methods of use
|
PL1846030T3
(pl)
|
2005-01-21 |
2019-05-31 |
Genentech Inc |
Ustalone dawkowanie przeciwciał her
|
WO2006084018A2
(en)
|
2005-02-02 |
2006-08-10 |
Monogram Biosciences, Inc. |
Methods for determining responsiveness to cancer therapy
|
CN103981190A
(zh)
|
2005-02-07 |
2014-08-13 |
罗氏格黎卡特股份公司 |
结合egfr的抗原结合分子,编码它的载体,及其应用
|
US7718626B2
(en)
|
2005-02-17 |
2010-05-18 |
University Of Maryland, Baltimore |
ErbB3 binding protein compositions and methods of use
|
AU2005327973A1
(en)
|
2005-02-23 |
2006-08-31 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents for modulating biological activity
|
UA95902C2
(ru)
|
2005-02-23 |
2011-09-26 |
Дженентек, Инк. |
Способ увеличения времени развития заболевания или выживаемости у раковых пациентов
|
US7210618B2
(en)
|
2005-03-03 |
2007-05-01 |
Nokia Corporation |
Mobile communication terminal
|
KR20080004480A
(ko)
|
2005-03-07 |
2008-01-09 |
타게티드 몰레큘라 다이아그노스틱스, 엘엘씨 |
티로신 키나제 억제제 조성물, 그의 제조 방법 및 이를이용한 질병 치료 방법
|
WO2006096861A2
(en)
|
2005-03-08 |
2006-09-14 |
Genentech, Inc. |
METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
|
JP5011277B2
(ja)
|
2005-04-06 |
2012-08-29 |
アイビーシー・ファーマシューティカルズ・インコーポレーテッド |
ホモダイマー、ホモテトラマーまたはダイマーのダイマーのからなる安定に連結された複合体を発生させるための方法および使用
|
JP5129122B2
(ja)
|
2005-04-26 |
2013-01-23 |
トリオン ファーマ ゲーエムベーハー |
癌治療のための抗体およびグルココルチコイドの組み合わせ
|
US20090298061A1
(en)
|
2005-07-29 |
2009-12-03 |
Siemens Healthcare Diagnostics Inc. |
Diagnostic Methods for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapy
|
KR101460932B1
(ko)
|
2005-08-26 |
2014-11-12 |
로슈 글리카트 아게 |
변형된 세포 신호 활성을 가진 개질된 항원 결합 분자
|
US20070172844A1
(en)
|
2005-09-28 |
2007-07-26 |
University Of South Florida |
Individualized cancer treatments
|
AU2006299429B2
(en)
|
2005-10-03 |
2012-02-23 |
Xencor, Inc. |
Fc variants with optimized Fc receptor binding properties
|
US20090252681A1
(en)
|
2005-10-11 |
2009-10-08 |
Ablynx N.V. |
Nanobodies and Polypeptides Against EGFR and IGF-IR
|
US20110052570A1
(en)
|
2005-10-26 |
2011-03-03 |
Children's Medical Center Corporation |
Method to prognose response to anti-egfr therapeutics
|
EP1792622A1
(en)
|
2005-11-11 |
2007-06-06 |
GPC Biotech AG |
Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues
|
HUE039353T2
(hu)
*
|
2005-12-13 |
2018-12-28 |
Lilly Co Eli |
Anti-IL-17 ellenanyagok
|
EP1800695A1
(en)
|
2005-12-21 |
2007-06-27 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Immuno-RNA-constructs
|
AR056857A1
(es)
*
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
US7498142B2
(en)
|
2006-01-31 |
2009-03-03 |
Yeda Research And Development Co., Ltd. |
Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
|
RU2008135318A
(ru)
|
2006-02-01 |
2010-03-10 |
Дзе Джонс Хопкинс Юниверсити (Us) |
Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии неопластических или инфекционных заболеваний
|
JP5374359B2
(ja)
|
2006-03-17 |
2013-12-25 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
安定化されたポリペプチド化合物
|
JP2009532393A
(ja)
|
2006-04-07 |
2009-09-10 |
コペンハーゲン ユニバーシティ |
ErbB受容体由来ペプチド断片
|
JP2009539836A
(ja)
|
2006-06-05 |
2009-11-19 |
ジェネンテック・インコーポレーテッド |
EGFまたはTGF−αのレベルの上昇が生じている癌患者の生存の延長
|
CN101627053A
(zh)
*
|
2006-06-12 |
2010-01-13 |
西福根有限公司 |
泛细胞表面受体特异的治疗剂
|
KR101571027B1
(ko)
|
2006-06-12 |
2015-11-23 |
이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 |
효과기 기능을 갖는 단일쇄 다가 결합 단백질
|
WO2007145832A2
(en)
|
2006-06-13 |
2007-12-21 |
Shulman Zachary J |
Infant harness support
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
US20100316626A1
(en)
|
2006-08-11 |
2010-12-16 |
The Government Of The United States Of America As Represented By The Secretary |
Methods for treatment and diagnosis of psychiatric disorders
|
US8936780B2
(en)
|
2006-08-30 |
2015-01-20 |
Advanced Cardiovascular Systems, Inc. |
Stimuli responsive polyester amide particles
|
PL2059533T3
(pl)
|
2006-08-30 |
2013-04-30 |
Genentech Inc |
Przeciwciała wieloswoiste
|
BRPI0715754A2
(pt)
|
2006-08-31 |
2013-07-09 |
Hoffmann La Roche |
mÉtodo para a produÇço de fator do crescimento similar Á insulina i
|
WO2011008990A1
(en)
|
2009-07-15 |
2011-01-20 |
Prometheus Laboratories Inc. |
Drug selection for gastric cancer therapy using antibody-based arrays
|
WO2008036802A2
(en)
|
2006-09-21 |
2008-03-27 |
Prometheus Laboratories Inc. |
Antibody-based arrays for detecting multiple signal transducers in rare circulating cells
|
US20080076139A1
(en)
|
2006-09-21 |
2008-03-27 |
Sharat Singh |
Methods and compositions for detecting the activation states of multiple signal transducers in rare circulating cells
|
BRPI0717416A2
(pt)
|
2006-09-21 |
2013-11-12 |
Prometheus Lab Inc |
Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
|
US20080112961A1
(en)
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
US20100248225A1
(en)
|
2006-11-06 |
2010-09-30 |
Bankaitis-Davis Danute M |
Gene expression profiling for identification, monitoring and treatment of melanoma
|
WO2008140493A2
(en)
|
2006-11-21 |
2008-11-20 |
The Regents Of The University Of Californina |
Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
|
WO2008064884A1
(en)
|
2006-11-28 |
2008-06-05 |
U3 Pharma Gmbh |
Activated her3 as a marker for predicting therapeutic efficacy
|
SG177225A1
(en)
|
2006-12-01 |
2012-01-30 |
Agency Science Tech & Res |
Cancer-related protein kinases
|
WO2008140603A2
(en)
|
2006-12-08 |
2008-11-20 |
Macrogenics, Inc. |
METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
|
US8362217B2
(en)
|
2006-12-21 |
2013-01-29 |
Emd Millipore Corporation |
Purification of proteins
|
US8569464B2
(en)
|
2006-12-21 |
2013-10-29 |
Emd Millipore Corporation |
Purification of proteins
|
US8163886B2
(en)
|
2006-12-21 |
2012-04-24 |
Emd Millipore Corporation |
Purification of proteins
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
CA2675014C
(en)
|
2007-01-17 |
2016-03-29 |
Immunomedics, Inc. |
Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
|
EP2647388A1
(en)
|
2007-02-16 |
2013-10-09 |
Merrimack Pharmaceuticals, Inc. |
Antibodies Against ERBB3 and Uses Thereof
|
NZ578824A
(en)
|
2007-03-02 |
2012-03-30 |
Genentech Inc |
Predicting response to a her dimerisation inhibitor based on low her3 expression
|
AR065803A1
(es)
|
2007-03-23 |
2009-07-01 |
Smithkline Beecham Corp |
Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
|
CN101636412A
(zh)
|
2007-03-30 |
2010-01-27 |
霍夫曼-拉罗奇有限公司 |
标记的和非标记的单克隆抗体的组合物
|
ES2529790T3
(es)
|
2007-04-13 |
2015-02-25 |
Dana-Farber Cancer Institute, Inc. |
Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
|
FR2915115B1
(fr)
|
2007-04-23 |
2010-09-10 |
Sames Technologies |
Organe de pulverisation,dispositif de projection comportant un tel organe,installation de projection et methode de nettoyage d'un tel organe
|
US20100240035A1
(en)
|
2007-06-01 |
2010-09-23 |
The Regents Of The University Of California |
Multigene prognostic assay for lung cancer
|
WO2008148546A2
(en)
|
2007-06-06 |
2008-12-11 |
F.Hoffmann-La Roche Ag |
Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a nir fluorescence label
|
WO2009045579A2
(en)
|
2007-06-14 |
2009-04-09 |
The Regents Of The University Of California |
Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics
|
WO2009003082A2
(en)
|
2007-06-26 |
2008-12-31 |
Vanderbilt University |
Immunological compositions as cancer biomarkers and/or therapeutics
|
EP2173377B1
(en)
|
2007-06-26 |
2017-11-29 |
University of Miami |
Antibody-endostatin fusion protein and its variants
|
LT3597659T
(lt)
|
2007-07-09 |
2023-05-10 |
Genentech, Inc. |
Disulfidinės jungties redukcijos prevencijos būdas gaminant polipeptidą rekombinantiniu būdu
|
JP5352585B2
(ja)
|
2007-07-13 |
2013-11-27 |
ネステク ソシエテ アノニム |
抗体アレイを用いた肺癌治療のための薬剤選択
|
WO2009023266A1
(en)
|
2007-08-14 |
2009-02-19 |
Ludwig Institute For Cancer Research |
Generation of antibodies to cell-surface receptors and cancer-associated proteins including egfr family members
|
MX349306B
(es)
|
2007-09-21 |
2017-07-19 |
Univ California |
Interferón de objetivo demuestra actividades potentes apoptóticas y antitumorales.
|
US20110091473A1
(en)
|
2007-10-22 |
2011-04-21 |
Genmab A/S |
Novel antibody therapies
|
US20120047586A9
(en)
|
2007-10-24 |
2012-02-23 |
Otsuka Chemical Co., Ltd |
Polypeptide having enhanced effector function
|
CN103399144B
(zh)
|
2008-02-25 |
2015-10-28 |
雀巢产品技术援助有限公司 |
用抗体阵列选择乳腺癌治疗药物
|
US20090226455A1
(en)
|
2008-03-06 |
2009-09-10 |
Genentech, Inc. |
Combination therapy with c-met and her antagonists
|
EP2106806A1
(en)
|
2008-03-31 |
2009-10-07 |
Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. |
Nanoparticles for targeted delivery of active agents to the lung
|
PL2288715T3
(pl)
|
2008-04-11 |
2015-03-31 |
Merrimack Pharmaceuticals Inc |
Łączniki będące albuminą surowicy ludzkiej i ich koniugaty
|
SG190572A1
(en)
|
2008-04-29 |
2013-06-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
BRPI0911442A2
(pt)
|
2008-04-30 |
2019-03-12 |
Immunogen, Inc. |
conjugados potentes e ligantes hidrofílicos
|
WO2009134870A1
(en)
|
2008-04-30 |
2009-11-05 |
Immunogen, Inc. |
Potent cell-binding agent drug conjugates
|
UY31800A
(es)
|
2008-05-05 |
2009-11-10 |
Smithkline Beckman Corp |
Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
|
BRPI0914789A2
(pt)
|
2008-06-16 |
2015-10-20 |
Immunogen Inc |
efeitos sinérgicos
|
EP2138511A1
(en)
|
2008-06-27 |
2009-12-30 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
HER3 as a determinant for the prognosis of melanoma
|
RU2011104348A
(ru)
|
2008-07-08 |
2012-08-20 |
Эбботт Лэборетриз (Us) |
Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
|
AU2009273540A1
(en)
|
2008-07-25 |
2010-01-28 |
Merck Patent Gmbh |
Method of determination of receptor binding saturation effected by monoclonal antibodies
|
US8056451B2
(en)
|
2008-07-28 |
2011-11-15 |
Irwin Industrial Tool Company |
Locking pliers
|
US20100033482A1
(en)
|
2008-08-11 |
2010-02-11 |
Interactive Relighting of Dynamic Refractive Objects |
Interactive Relighting of Dynamic Refractive Objects
|
PE20120015A1
(es)
|
2008-08-15 |
2012-01-26 |
Merrimack Pharmaceuticals Inc |
Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico
|
US8080415B2
(en)
|
2008-09-26 |
2011-12-20 |
Eureka Therapeutics, Inc. |
Modified host cells and uses thereof
|
US8734795B2
(en)
|
2008-10-31 |
2014-05-27 |
Biogen Idec Ma Inc. |
Light targeting molecules and uses thereof
|
EP2361098B1
(en)
|
2008-10-31 |
2019-08-28 |
The General Hospital Corporation |
Compositions and methods for delivering a substance to a biological target
|
BRPI0921586A2
(pt)
|
2008-11-18 |
2019-09-24 |
Merrimack Pharmaceuticals Inc |
articuladores de albumina de soro humana e conjugados destes
|
US20100169729A1
(en)
|
2008-12-30 |
2010-07-01 |
Datta Shamanna M |
Enabling an integrated memory controller to transparently work with defective memory devices
|
JP5907732B2
(ja)
|
2009-01-14 |
2016-04-26 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
比に基づく生体マーカーおよびそれを使用する方法
|
EP2387711B1
(en)
|
2009-01-15 |
2015-04-22 |
Laboratory Corporation of America Holdings |
Methods of determining patient response by measurement of her-3
|
WO2010083463A1
(en)
|
2009-01-15 |
2010-07-22 |
Laboratory Corporation Of America Holdings |
Methods of determining patient response by measurement of her-2 expression
|
EP3470087A1
(en)
|
2009-02-13 |
2019-04-17 |
Immunomedics, Inc. |
Lyophilised compositions of immunoconjugates with an intracellularly-cleavable linkage
|
WO2010097186A1
(en)
|
2009-02-24 |
2010-09-02 |
Roche Diagnostic Gmbh |
Use of s-erbb-3 as a marker for cancer
|
US20110313137A1
(en)
|
2009-02-25 |
2011-12-22 |
Dongxing Zha |
Her2 antibody compositions
|
MA33198B1
(fr)
|
2009-03-20 |
2012-04-02 |
Genentech Inc |
Anticorps anti-her di-spécifiques
|
US8362215B2
(en)
|
2009-04-29 |
2013-01-29 |
Trellis Bioscience, Llc |
Antibodies immunoreactive with heregulin-coupled HER3
|
JP5705836B2
(ja)
|
2009-05-29 |
2015-04-22 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Her2を発現する胃癌患者のher2シグナル伝達のためのモジュレーター
|
JP5918129B2
(ja)
|
2009-06-22 |
2016-05-18 |
メディミューン,エルエルシー |
部位特異的共役のための操作されたFc領域
|
MX346115B
(es)
|
2009-08-06 |
2017-03-08 |
Genentech Inc * |
Metodo para mejorar la eliminación de virus en la purificacion proteica.
|
US20110039300A1
(en)
|
2009-08-10 |
2011-02-17 |
Robert Bayer |
Antibodies with enhanced adcc functions
|
JP5752687B2
(ja)
|
2009-08-21 |
2015-07-22 |
メリマック ファーマシューティカルズ インコーポレーティッド |
Erbb3の外部ドメインに対する抗体およびその使用
|
EP2475390A4
(en)
|
2009-09-09 |
2014-01-01 |
Quintiles Transnat Corp |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF TYROSINE KINASE RECEPTOR MEDIATION DISEASES OR DISORDERS
|
AU2010303415B2
(en)
|
2009-10-07 |
2015-02-19 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
JP2013507378A
(ja)
|
2009-10-09 |
2013-03-04 |
メルク・シャープ・エンド・ドーム・コーポレイション |
抗her3抗体の製造、特徴づけ及びその用途
|
EP2488199A1
(en)
|
2009-10-14 |
2012-08-22 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
|
CN105999263B
(zh)
|
2009-11-13 |
2021-06-29 |
第一三共欧洲有限公司 |
用于治疗或预防人表皮生长因子受体-3(her-3)相关疾病的材料和方法
|
MX2012008958A
(es)
|
2010-02-18 |
2012-08-23 |
Genentech Inc |
Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
|
EP2542699A4
(en)
|
2010-03-03 |
2013-10-02 |
Targeted Molecular Diagnostics Llc |
METHODS FOR DETERMINING REACTIVITY TO A MEDICINE BASED ON DETERMINATION OF RAS MUTATION AND / OR RAS AMPLIFICATION
|
DK2544680T3
(en)
|
2010-03-11 |
2015-04-27 |
Merrimack Pharmaceuticals Inc |
USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
|
US8481687B2
(en)
|
2010-04-09 |
2013-07-09 |
Aveo Pharmaceuticals, Inc. |
Anti-ErbB3 antibodies
|
WO2011139629A2
(en)
|
2010-04-26 |
2011-11-10 |
Biogen Idec Ma Inc. |
Light targeting molecules and uses thereof
|
WO2011143414A1
(en)
|
2010-05-13 |
2011-11-17 |
Fox Chase Cancer Center |
RECOMBINANTLY PRODUCED ANTIBODIES TARGETING ErbB SIGNALING MOLECULES AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF DISEASE
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
CN102906118B
(zh)
|
2010-05-20 |
2017-07-28 |
埃博灵克斯股份有限公司 |
与her3相关的生物材料
|
WO2012103341A1
(en)
|
2011-01-27 |
2012-08-02 |
Merrimack Pharmaceuticals, Inc. |
Treatment of advanced solid stage tumors using anti-erbb3 antibodies
|
RU2013140685A
(ru)
|
2011-02-04 |
2015-03-10 |
Дженентек, Инк. |
ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ
|
WO2012106578A1
(en)
|
2011-02-04 |
2012-08-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc)
|
US8952132B2
(en)
|
2011-02-07 |
2015-02-10 |
Research Development Foundation |
Engineered immunoglobulin FC polypeptides
|
US9574003B2
(en)
|
2011-03-06 |
2017-02-21 |
Merck Serono S.A. |
Low fucose cell lines and uses thereof
|
WO2012125807A2
(en)
|
2011-03-17 |
2012-09-20 |
Cernostics, Inc. |
Systems and compositions for diagnosing barrett's esophagus and methods of using the same
|